$OMER Remember, the biggest "secret" on Wall Street about Omeros is that narsoplimab WORKS in IgAN, and the Street thinks it doesn't. This is a rare opportunity where "smart" money is dead wrong. It is as sure a thing as any that IgAN will read out a positive phase 3, that will draw in hundreds of millions of new investment. All that price that left the stock in Q4 2018 will come back in overnight. This is the biggest safety net in my opinion because it is a strong positive that is already a consensus failure, and is near entirely priced out.